Importantly, the vigorous signature in SLE, Sjögren’s, and NMO, contrasts with the subnormal serum type I IFN activity and WBC responses to IFN in most MS patients (Table 2). The gene discussed is IFNA1; the disease is systemic lupus erythematosus.